Overview
Geoffrey von Maltzahn, PhD, co-founded Generate Biomedicines, a Somerville clinical-stage biotechnology company founded in 2018 at Flagship Pioneering that applies generative biology — machine learning combined with high-throughput protein experimentation — to program novel protein therapeutics. Generate’s media center and homepage describe a new kind of therapeutics company at the intersection of machine learning, biological engineering, and medicine pioneering Generative Biology.
Through the Generate Platform, the company studies millions of proteins to learn generalizable rules by which nature encodes function, then uses those rules to generate novel medicines with specific therapeutic functions.
Role and company
As Co-Founder, von Maltzahn helped establish Generate alongside co-founders Molly Gibson, PhD, Avak Kahvejian, PhD, and Gevorg Grigoryan, PhD, following Flagship Labs explorations merging complementary protein-design initiatives in 2019 per Generate media materials. Mike Nally serves as chief executive officer per Generate investor leadership disclosures.
Generate reports 42,000 proteins generated, built, and tested, five clinical-stage molecules, and 140,000+ square feet of laboratory space in Boynton Yards and Andover per homepage materials reviewed 2026.
Background and career context
Generate media center identifies von Maltzahn as co-founder from 2018 Flagship Pioneering launch without a dedicated individual biography page on generatebiomedicines.com reviewed July 2026. His public record through Generate is tied to generative biology co-invention and Flagship portfolio company formation alongside Gibson, Kahvejian, and Grigoryan.
von Maltzahn’s co-founding role connects to Flagship’s broader programmable medicine thesis — treating protein design as a computational engineering discipline rather than purely empirical screening.
Company-building or leadership context
Flagship Pioneering launched Generate in 2018 after merging two Flagship Labs projects exploring machine learning for protein structure and generative biomedicine design. von Maltzahn and Kahvejian were initial co-CEO leaders before Nally’s 2021 appointment brought Pfizer global vaccines scaling experience per Generate media disclosures.
Generate completed major financings including the largest biotech Series C of 2023 per company communications and advanced GB-0895 anti-TSLP antibody toward global Phase 3 studies — milestones von Maltzahn’s founding science enabled.
Public milestones
2018: Generate Biomedicines founded at Flagship Pioneering; von Maltzahn among co-founders. October 9, 2025: First-in-human results for GB-0669 AI-designed antibody published on Generate media center. May 2026: Generate participating in Goldman Sachs Global Healthcare Conference per media center. Homepage cites 42,000+ proteins generated and tested.
von Maltzahn co-founder status documented in Generate media center and investor materials reviewed July 10, 2026.
Why their work matters
Generate under von Maltzahn’s co-founding vision demonstrates generative biology at clinical scale — AI-designed GB-0669 first-in-human data and GB-0895 Phase 3 trajectory compress traditional biologics timelines when platform and pipeline align. von Maltzahn represents Flagship’s generative biology founder cohort shaping how pharma evaluates programmable protein assets.
For healthcare AI readers, Generate is therapeutic generative AI — distinct from clinical workflow AI but defining the biologic drug generation frontier.
Sources and references
Primary sourcing: Generate Biomedicines media center and homepage, reviewed July 10, 2026.
- Generate — Media Center (generatebiomedicines.com)
- Generate — Homepage (generatebiomedicines.com)
Co-founder status from Generate media and investor materials. No personal education claims beyond co-founder identification on cited pages.
Generate homepage describes a living feedback loop where machine learning drives generative protein design and experimentation continuously trains the system in real time — a compounding discovery model von Maltzahn’s co-founding helped establish at Flagship Pioneering. October 2025 first-in-human GB-0669 AI-designed antibody results on Generate media center illustrate programmable biology reaching clinical validation under platform von Maltzahn co-created.
Generate reports 140,000+ square feet in Boynton Yards and Andover locations and collectively unstoppable team dedicated to democratizing biotherapeutics per homepage — scale indicators von Maltzahn’s Flagship co-founding enabled alongside co-founders Gibson, Kahvejian, and Grigoryan before Mike Nally’s CEO appointment brought enterprise biopharma scaling experience.